| Chronic Wound | Patho-Genesis of Pain | Pain Management Treatment | Mechanism of Action | Result of Treatment |
| Ischemic (Arterial insufficiency) ulcer | Ischemia | Regional sympathetic blockade | Dilation of smooth muscles in venules and arterioles | Decrease in peripheral resistance, increase in capillary blood flow |
| Ischemic ulcer |
| Lumbar sympathetic blockade | Percutaneous block of lumbar sympathetic chain | Similar to regional blockade |
| Ischemic ulcer |
| Spinal cord stimulation | Placement of electrodes in epidural space for spinal cord dorsal column stimulation | Increased local blood flow |
| Sickle cell ulcer | Micro-circulatory occlusion | Opioids | Patient-controlled analgesia (PCA) | Pain relief |
| Sickle cell ulcer |
|
| Epidural analgesia (for patients not responding to PCA) | Pain relief |
| Diabetic foot ulcer | Neuropathy, caused by nervous system deterioration (specifically axonal degeneration and segmental demyelination | Tricyclic antidepressants (TCA): amitryptiline, desipramine | Inhibition of reuptake of serontonin and norepinephrine | Relief of neuropathic pain |
| Diabetic foot ulcer |
| Anticonvulsants: phenytoin, carbamazepine, gabapentin |
| Relief of neuropathic pain |
| Diabetic foot ulcer |
| Mexilitene | Analgesic effect | Relief of neuropathic pain |
| Venous ulcer | Venous reflux causing increased capillary permeability and extravasation of fluids and proteins | EMLA® (eutectic mix of local anesthetics: lidocaine and prilocaine) | Topical application, facilitating debridement | Relief of associated pain |
| Venous ulcer |
| Systemic analgesics: Level 1, TCAs, tramadol and acetaminophen; Level 2, codeine, oxycodone, and hydrocodone; Level 3, stronger opioids | Analgesic effect | Relief of associated pain |
| Pressure ulcer | Constant pressure to the skin and muscle | Non-opioid analgesics: ketorolac | Intravenous administration; analgesic effect | Relief of associated pain |